Liquidia Corp
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
LQDA | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 419 DAVIS DRIVE, SUITE 100, 27560 MORRISVILLE
- Website:
- https://www.liquidia.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare cardiopulmonary diseases. The company specializes in treating conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia utilizes its proprietary PRINT® technology, a particle engineering platform, to enhance the efficacy, tolerability, and convenience of its medicines. A key product in its portfolio is YUTREPIA™ (treprostinil) inhalation powder, an approved therapy designed to improve outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Liquidia Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Liquidia Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Liquidia Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
